- Home
- HNRG vs TERN Comparison
HNRG vs TERN Comparison
Compare HNRG & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- TERN
- Stock Information
- Founded
- HNRG 1949
- TERN 2017
- Country
- HNRG United States
- TERN United States
- Employees
- HNRG N/A
- TERN N/A
- Industry
- HNRG Coal Mining
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- HNRG Energy
- TERN Health Care
- Exchange
- HNRG Nasdaq
- TERN Nasdaq
- Market Cap
- HNRG 823.6M
- TERN 710.6M
- IPO Year
- HNRG N/A
- TERN 2021
- Fundamental
- Price
- HNRG $19.33
- TERN $26.28
- Analyst Decision
- HNRG Strong Buy
- TERN Buy
- Analyst Count
- HNRG 4
- TERN 11
- Target Price
- HNRG $20.00
- TERN $22.79
- AVG Volume (30 Days)
- HNRG 549.3K
- TERN 5.4M
- Earning Date
- HNRG 11-10-2025
- TERN 11-10-2025
- Dividend Yield
- HNRG N/A
- TERN N/A
- EPS Growth
- HNRG N/A
- TERN N/A
- EPS
- HNRG N/A
- TERN N/A
- Revenue
- HNRG $461,142,000.00
- TERN N/A
- Revenue This Year
- HNRG $11.19
- TERN N/A
- Revenue Next Year
- HNRG $4.79
- TERN N/A
- P/E Ratio
- HNRG N/A
- TERN N/A
- Revenue Growth
- HNRG 7.15
- TERN N/A
- 52 Week Low
- HNRG $8.37
- TERN $1.87
- 52 Week High
- HNRG $24.70
- TERN $28.49
- Technical
- Relative Strength Index (RSI)
- HNRG 43.66
- TERN 80.56
- Support Level
- HNRG $19.63
- TERN $7.87
- Resistance Level
- HNRG $21.80
- TERN $28.49
- Average True Range (ATR)
- HNRG 1.47
- TERN 2.03
- MACD
- HNRG -0.24
- TERN 0.73
- Stochastic Oscillator
- HNRG 5.93
- TERN 83.22
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.